IDO1 and arthritic joint disease: In fact, sCD83 administration resulted in a long-term and antigen-specific immunomodulation in arthritis by upregulating IDO1 and TGF-β, reducing auto-aggressive effector T cells, inducing Treg cells, and promoting a direct impairment of osteoclastogenesis [40].